Investigational drug · Phase 3
Oleclumab
Also called: MEDI9447
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
28
Any phase or sponsor naming "Oleclumab"
First trial start
2017
Dec 18, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Oleclumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Non-small Cell Lung Cancer
- Metastatic Microsatellite-stable Colorectal Cancer
- Triple Negative Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Oleclumab" as an intervention, largest first.
- A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05221840 · 1,051 participants · Start Feb 7, 2022 · Primary completion Jan 8, 2027
Drug: Durvalumab; Oleclumab and 1 more · For: Non-Small Cell Lung Cancer
Sites: San Diego, California; New Haven, Connecticut; Stuart, Florida · 202 sites in all
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05061550 · 630 participants (planned) · Start Apr 14, 2022 · Primary completion May 28, 2030
Drug: Durvalumab; Oleclumab and 10 more · For: Non-small Cell Lung Cancer
Sites: Little Rock, Arkansas; Los Angeles, California; Oakland, California · 97 sites in all
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03334617 · 528 participants · Start Dec 18, 2017 · Primary completion Sep 13, 2024
Drug: Durvalumab; Danvatirsen and 6 more · For: Non-Small Cell Lung Cancer
Sites: Duarte, California; Fullerton, California; La Jolla, California · 45 sites in all
AstraZenecaAstraZeneca (AZN)
NCT02740985 · 313 participants · Start Jun 17, 2016 · Primary completion Dec 31, 2020
Drug: AZD4635; Durvalumab and 4 more · For: Advanced Solid Malignancies; Non-Small Cell Lung Cancer (NSCLC); Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) and 1 more
Sites: Fayetteville, Arkansas; Fresno, California; Denver, Colorado · 17 sites in all
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03742102 · 243 participants · Start Dec 21, 2018 · Primary completion Nov 29, 2024
Drug: Durvalumab; Capivasertib and 4 more · For: Triple Negative Breast Neoplasms
Sites: Tucson, Arizona; Columbia, Maryland; Boston, Massachusetts · 32 sites in all
- MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.Pivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT03611556 · 213 participants · Start Jun 21, 2018 · Primary completion Jul 22, 2022
Drug: Oleclumab; Durvalumab and 5 more · For: Carcinoma; Metastatic Pancreatic Adenocarcinoma
Sites: La Jolla, California; Aurora, Colorado; Fort Myers, Florida · 27 sites in all
MedImmune LLCAstraZeneca (AZN)
NCT02503774 · 192 participants · Start Jul 24, 2015 · Primary completion Jan 22, 2021
Drug: Oleclumab; Durvalumab · For: Solid Tumors
Sites: La Jolla, California; New Haven, Connecticut; Gainesville, Florida · 18 sites in all
- Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT03822351 · 189 participants · Start Dec 19, 2018 · Primary completion Jul 18, 2023
Drug: Durvalumab + Oleclumab; Durvalumab and 1 more · For: Stage III Non-small Cell Lung Cancer; Unresectable
Sites: Anaheim, California; Duarte, California; Sacramento, California · 73 sites in all
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03819465 · 175 participants · Start Dec 27, 2018 · Primary completion May 23, 2023
Drug: Durvalumab; Danvatirsen and 8 more · For: Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sites: Iowa City, Iowa; Pittsburgh, Pennsylvania; Nashville, Tennessee · 41 sites in all
- Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:Pivotal-lookingActive, not recruiting
Jules Bordet InstituteAcademic, hospital or other
NCT03875573 · 147 participants · Start Nov 6, 2019 · Primary completion Nov 30, 2024
Drug: Durvalumab; Oleclumab · For: Luminal B
Sites: Brussels, Belgium; Leuven, Belgium; Namur, Belgium · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.
McGrath L, Kar G, Bonanno L, et al. · Nature 2026
- Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy.
Tandaric L, Bjørge L, Lode MR, et al. · Mol Oncol 2026
- Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
Schmid P, Ma CX, Park YH, et al. · Clin Cancer Res 2026
- Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.
De Caluwé A, Desmoulins I, Cao K, et al. · Nat Med 2026
- MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer.
Cho BC, Charoentum C, Kim DW, et al. · Lung Cancer 2026
- Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
Cascone T, Bonanno L, Guisier F, et al. · Nat Med 2025
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.